Phase 3Terminated
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
- Sponsor
- Pfizer (Industry)
- Enrollment
- 755 enrolled
- Conditions
- Mixed Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin; atorvastatin
- Ages
- adults, older adults
- Registry
- NCT00134238
Full record on ClinicalTrials.gov
From the registry
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia
Primary outcomes
- Change in intima media thickness as measured by carotid ultrasound
History
Last registry update
Primary completion
Registered
Started